Your browser doesn't support javascript.
loading
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
Heath, Elisabeth; Heilbrun, Lance; Mannuel, Heather; Liu, Glenn; Lara, Primo; Monk, J Paul; Flaig, Thomas; Zurita, Amado; Mack, Philip; Vaishampayan, Ulka; Stella, Philip; Smith, Daryn; Bolton, Susan; Hussain, Arif; Al-Janadi, Anas; Silbiger, Daniel; Usman, Muhammad; Ivy, S Percy.
Affiliation
  • Heath E; Department of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, Michigan, USA heathe@karmanos.org.
  • Heilbrun L; Department of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, Michigan, USA.
  • Mannuel H; Division of Hematology/Oncology, University of Maryland School of Medicine and Greenebaum Cancer Center, Baltimore, Maryland, USA.
  • Liu G; Division of Hematology/Oncology, University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, Wisconsin, USA.
  • Lara P; Division of Hematology/Oncology, University of California Davis School of Medicine and Cancer Center, Sacramento, California, USA.
  • Monk JP; Division of Medical Oncology, Ohio State University School of Medicine and Cancer Center - James, Columbus, Ohio, USA.
  • Flaig T; Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Zurita A; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Mack P; Division of Hematology/Oncology, University of California Davis School of Medicine and Cancer Center, Sacramento, California, USA.
  • Vaishampayan U; Department of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, Michigan, USA.
  • Stella P; IHA Hematology/Oncology, Ypsilanti, Michigan, USA.
  • Smith D; Department of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, Michigan, USA.
  • Bolton S; Department of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, Michigan, USA.
  • Hussain A; Division of Hematology/Oncology, University of Maryland School of Medicine and Greenebaum Cancer Center, Baltimore, Maryland, USA.
  • Al-Janadi A; Michigan State University Breslin Cancer Center, Lansing, Michigan, USA.
  • Silbiger D; Case Western Reserve University School of Medicine University Hospitals, Cleveland, Ohio, USA.
  • Usman M; Department of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, Michigan, USA.
  • Ivy SP; National Institutes of Health National Cancer Institute, Bethesda, Maryland, USA.
Oncologist ; 24(9): 1149-e807, 2019 09.
Article in En | MEDLINE | ID: mdl-31152080
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Prostatic Neoplasms, Castration-Resistant Type of study: Clinical_trials Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Oncologist Journal subject: NEOPLASIAS Year: 2019 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Prostatic Neoplasms, Castration-Resistant Type of study: Clinical_trials Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Oncologist Journal subject: NEOPLASIAS Year: 2019 Type: Article Affiliation country: United States